HRTIS — Herantis Pharma Oyj Share News
0.000.00%
Last trade - 00:00Brief: Herantis Pharma H1 Net Loss Widens To EUR 4.5 Mln
Brief: Herantis Pharma To Raise EUR 6.8 Mln Via Directed Share Offering
Brief: Herantis Pharma Appoints New CEO
Brief: Herantis Pharma Says Covid-19 May Require Rescheduling Of Planned Treatments
Brief: Herantis Pharma H2 Loss For The Period Widens To EUR 4.7 Mln
Brief: Herantis Announces Topline Results Of Phase 1-2 CDNF Trial
Brief: Herantis Pharma Updates On Non-Invasive Next Generation CDNF (xCDNF) Development
Brief: Herantis Pharma Completes Patient Treatments In Main Study Of Phase 1-2 CDNF Trial In Parkinson's Disease
Brief: Herantis Pharma: Directed Share Issue Oversubscribed
Brief: Herantis Pharma Commences Directed Share Issue, Contemplates Secondary Listing On Nasdaq First North Growth Market Sweden
Brief: Herantis Pharma Provides Update On Timeline For Ongoing Phase 1-2 CDNF Trial
Brief: Herantis Pharma H1 Net Loss Widens To EUR 3.3 Million
Brief: Herantis Announces Follow-Up Review From Phase 1 Lymfactin Trial In Breast Cancer-Associated Lymphedema
Brief: Herantis Pharma To Expand Phase 2 AdeLE Clinical Trial
Brief: Herantis Pharma: Positive Outcome Of Directed Share Issue Raising EUR 5.8 Mln
Brief: Herantis Pharma: Update On Contemplated Directed Share Issue
Brief: Herantis Pharma H2 Net Result Swings To Profit EUR 2.4 Million
Brief: Herantis Pharma PLC Is Planning A Directed Share Issue
Brief: Herantis Pharma H1 Net Loss At EUR 1.8 Million